Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Urelumab - Bristol-Myers Squibb

Next Previous
X
Search
Drug Profile

Urelumab - Bristol-Myers Squibb

Alternative Names: Anti-4-1BB monoclonal antibody; Anti-CD137 monoclonal antibody - Medarex/Bristol-Myers Squibb; BMS-663513; BMS-66513; ONO-4481

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medarex
  • Developer Bristol-Myers Squibb; National Cancer Institute (USA); Ono Pharmaceutical; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Chicago
  • Class Antineoplastics; Disulfides; Immunoglobulins; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-Hodgkin's lymphoma; Solid tumours
  • No development reported Colorectal cancer; Glioblastoma; Head and neck cancer; Malignant melanoma; Multiple myeloma
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 03 Oct 2023 National Cancer Institute (NCI) and Bristol Myers Squibb completes a phase-I development in Glioblastoma (Monotherapy, Combination therapy, Recurrent, Second-line therapy or greater) in USA (IV, Infusion) (NCT02658981)
  • 28 Jun 2022 No recent reports of development identified for phase-I development in Glioblastoma(Combination therapy, Recurrent, Second-line therapy or greater) in USA (IV, Infusion)
  • 28 Jun 2022 No recent reports of development identified for phase-I development in Glioblastoma(Monotherapy, Recurrent, Second-line therapy or greater) in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top